- Added Capabilities to Help Accelerate Sales Growth of Existing
Products and Prepare for New Product Launches -
VANCOUVER, Sept. 9 /CNW/ - Neovasc Inc. (TSXV: NVC), a new specialty
vascular device company comprised of the former Medical Ventures Corp.,
Neovasc Medical Ltd. and B-Balloon Ltd., today announced executive
appointments to newly created marketing and sales positions. Cynthia Roney,
who was appointed vice president of marketing, has more than 20 years of
medical device senior management and marketing experience, and Sean Moore, who
was named vice president of sales, has medical sales expertise in both Canada
and the U.S.
"These additions to the senior management team reflect Neovasc's ongoing
strategic progress as we integrate our three businesses and move to fully
capitalize on the commercial potential of our innovative vascular and surgical
devices," said Alexei Marko, chief executive officer of Neovasc. "These senior
managers have track records of success and a range of medical device expertise
that will be especially valuable as we ramp up our product commercialization
and marketing efforts."
Neovasc's Metricath(R) for intravascular measurement and its
PeriPatch(TM) and Aegis(TM) surgical tissue and staple line reinforcement
products help doctors treat a wide range of health conditions more effectively
and efficiently. Neovasc is also developing the Reducer(R), a device with
breakthrough potential as a therapy for refractory angina, as well as novel
stents specially designed for hard-to-treat ostial arterial lesions.
"This is an exciting time to join Neovasc, as the company prepares for a
number of upcoming product launches and advances its expanded product
pipeline," said Ms. Roney. "As a veteran medical device executive, I
appreciate the focus, sense of urgency and commitment of this talented team,
as we work together to take full advantage of these opportunities and help
drive the growth of Neovasc."
Ms. Roney previously was president and chief executive officer of Xillix
Technologies Corp., which was acquired by Novadaq Technologies Inc. At Xillix,
she was instrumental in the successful development and commercialization of an
innovative device for the early detection of lung cancer. Prior to Xillix, Ms.
Roney managed sales of cardiac devices at Physio-Control, later acquired by
Medtronic. Earlier in her career she held sales and marketing positions at
Baxter Healthcare. Ms. Roney holds a B.A. in Economics from the University of
Sean Moore was director of sales at Medical Ventures Corp. Previously, he
helped establish a direct sales operation in Canada as an area manager at
ConMed Corporation. As head of ConMed's Southeast U.S. sales, Mr. Moore
surpassed sales quotas for nine consecutive quarters and was named Area
Director of the Year. Previously, he managed sales of surgical devices at
Covidien (formerly Tyco Healthcare). Mr. Moore holds a B.B.A. degree from
Trinity Western University in British Columbia.
About Neovasc Inc.
Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty
vascular device company that develops, manufactures and markets medical
devices for the rapidly growing vascular and surgical marketplace. Neovasc is
comprised of the former Medical Ventures, Neovasc Medical Ltd. and B-Balloon
Ltd. The company's current products include, Metricath(R) for intravascular
measurement and PeriPatch(TM) surgical tissue and staple line reinforcement
products. Neovasc has a development pipeline of innovative new products, and
provides contract medical device development and manufacturing services. For
more information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects," and
"will" and words of similar import, constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, among others, the following: general economic and business
conditions, both nationally and in the regions in which the Company operates;
history of losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product candidates,
ability to properly integrate newly acquired businesses, technology changes;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; liability
and other claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking statements
are reasonable based on the information available to it on the date such
statements were made, no assurances can be given as to the future results,
approvals or achievements. Given these uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements. The Company
does not assume the obligation to update any forward-looking statements except
as otherwise required by applicable law.
For further information:
For further information: Corporate contact: Neovasc Inc., Chris Clark,
(604) 249-4138; U.S. media & investor contact: GendeLLindheim BioCom Partners,
Barbara Lindheim, (212) 918-4650